Targeted IL-2 therapy to reduce inhibitor antibodies in hemophilia
Official title: Immunocytokine therapy for immune modulation in hemophilia
Funded at Indiana University Indianapolis · NIH-11252575 · Data updated 2026-11-12
This project uses a new IL-2–based immunocytokine (F5111) to boost regulatory immune cells and lower antibodies that block clotting factor treatment in people with hemophilia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project start | January 1, 2025 |
| Project end | November 30, 2026 |
| Funding year | 2026 |
| Award (this year) | $524,214 |
| NIH project number | 5R33HL177497-02 |
| Project ID | NIH-11252575 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal future trial candidates would be people with hemophilia A or B who have developed inhibitors to replacement clotting factors or who are at high risk of developing inhibitors.
✕Less likely to help
People without immune-mediated inhibitor problems, or whose bleeding is controlled without factor replacement, are unlikely to benefit from this immune‑modulation approach.
What this research studies
This project will develop and characterize an IL-2–based immunocytokine (called F5111) designed to preferentially expand regulatory T cells that promote tolerance to clotting factor therapy. Researchers will study the drug's dosing, safety, duration in the body, and mechanism using laboratory and animal models of hemophilia, including models that mimic inhibitor formation and anaphylactic reactions. The goal of these preclinical studies is to show the approach lowers inhibitor formation and has fewer off-target immune effects so it can move toward human testing.
Why it matters
Potential benefit: If successful, this approach could prevent or reduce inhibitor antibodies that make clotting factor therapy ineffective, lowering bleeding risk and treatment burden for people with hemophilia.
How similar studies have gone: Low‑dose IL‑2 has expanded regulatory T cells in other immune diseases, but IL‑2–based immunocytokines like F5111 are a newer, less-tested approach in hemophilia.
Where this research is happening
-
Indiana University Indianapolis
Indianapolis, United States Active
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
Related research
Other NIH-funded projects on the same topics.
-
cGMP production of FVIII-making placental cells to help people with Hemophilia A
A new, patient-friendly therapy aims to make FVIII-producing placental cells in the lab to help adults with Hemophilia A, potentially offering a longer-lasting and more affordable treatment.
-
Enhancing immune regulation in gene therapy for hemophilia (new approaches to safer treatment)
A patient-focused overview of a long-running NIH grant exploring how to make gene therapy for hemophilia safer by teaching the body’s immune system to tolerate the therapeutic protein.
-
A safer, longer-lasting gene delivery approach for Hemophilia A using improved nonviral vectors
Researchers are testing a new type of nonviral gene delivery that could provide longer expression of a therapeutic gene for adults with Hemophilia A.
-
Non-viral gene therapy approach to permanently fix hemophilia B
A new gene therapy approach aims to permanently correct hemophilia B without using viruses, potentially reducing bleeding events for people with this condition.
-
Hemophilia Point-of-Care Test Gets Regulatory Ready
A new point-of-care test for hemophilia A measures FVIII and emicizumab to help doctors manage bleeding risk quickly, with plans to obtain regulatory clearance.
-
Hemophilia A: studying why some people develop inhibitors to FVIII across families
This NIH grant funds a multi-year program to follow families affected by severe hemophilia A to understand why some individuals develop antibodies against factor VIII.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.